Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis

The requested reference [156c3d625a43d01f09a7f300654fb6fc8c36689c] no longer exists in our database. It has been replaced by the current reference: [78aa7070e86b3911a58cde072b2f3b7f6132c9fd]

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2011
The purpose of this study is to evaluate the activity of oral AB1010, administered at two dose levels during 3 years to patients with primary or secondary progressive multiple sclerosis.
Epistemonikos ID: bba8ddb5e74c789fd3beac98b1c02729c7130af1
First added on: Mar 31, 2022